Purespring Therapeutics raises £80/$105 million in a Series B …

Oct 9, 2024 · Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy …

CouponFollow Extension

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy …

purespringtx.com

$105
OFF

Purespring Bottles Up $105M Series B For Kidney Gene Therapy

6 days from now

Oct 9, 2024 · London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series …

fiercebiotech.com

$104
OFF

Advancing Gene Therapy For Kidney Disease, Purespring Adds £80M

6 days from now

Oct 9, 2024 · A preview of the next edition of BioWorld, Oct. 9, 2024. Purespring Therapeutics Ltd. has raised £80 million (US$104.6 million) in a series B, putting it on course to be the first …

bioworld.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

yahoo.com

€96
OFF

Purespring Bags £80m To Transform Kidney Disease Treatment

6 days from now

Oct 21, 2024 · Purespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.

european-biotechnology.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Sep 10, 2024 · Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA …

synconaltd.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

globenewswire.com

FAQs about Purespring Therapeutics raises £80/$105 million in a Series B … Coupon?

Will purespring bring kidney-tweaking gene therapy to the clinic?

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash. ...

What effects does ginseng have on chronic kidney disease?

Ginseng or its active metabolite, ginsenoside, is reported to be effective in treatment of various immune, endocrine, cardiovascular, and neurodegenerative diseases. Ginsenoside protected the kidneys from cisplatin-induced renal injury via an amelioration of oxidative stress and an inhibition of DNA fragmentation. ...

How does purespring treat kidney disease?

Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated viral (AAV) gene therapy platform. The Company currently has a pipeline of programmes in development. ...

Does purespring therapeutics have a kidney nephropathy program?

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney. The Series B funding announced Wednesday was led by Sofinnova Partners and will support Purespring’s initiation of a Phase 1/2 study of its lead candidate for IgA nephropathy, or IgAN. ...

Does purespring have nephropathy data?

Purespring plans to present their IgA nephropathy data publicly for the first time at the American Society of Nephrology Kidney Week congress on Oct. 26. There are currently no approved cell or gene therapies that treat kidney diseases. Many patients instead rely on dialysis or transplants, which both struggle with issues of equitable access. ...

What will purespring's fund raise for IgA nephropathy (IgAN)?

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) ...